Bladder-sparing drug combo for muscle invasive bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat muscle-invasive bladder cancer. The goal is to see if this can help patients avoid having their bladder removed. It is for people who cannot or choose not to have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have bladder cancer that has grown into the muscle layer (stage T2 to T4a) and may have spread to nearby lymph nodes (N0 or N1).
- You cannot have had certain treatments before, like chemotherapy or immunotherapy for bladder cancer.
- Your cancer must not have certain rare cell types (like more than 10% plasmacytoid or any small cells).
- You must be in fairly good health, able to do most daily activities (ECOG 0 or 1).
- Women who could become pregnant must use effective birth control, and men must not donate sperm during and for a period after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs, enfortumab vedotin and pembrolizumab, to see if they can help people with muscle-invasive bladder cancer avoid removing their bladder. The drugs are given before the standard surgery to possibly shrink the tumor and improve outcomes.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
This trial tests whether two drugs (enfortumab vedotin and pembrolizumab) work better than radiation with chemotherapy for muscle-invasive bladder cancer. The goal is to treat your cancer while keeping your bladder instead of removing it.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) plus radiation therapy for people with bladder cancer that has grown into the muscle layer. The goal is to see if this treatment can kill the cancer while avoiding the need for bladder removal surgery.
This Phase 2 study tests how well two anti-cancer medicines—enfortumab vedotin and pembrolizumab—work for people with muscle-invasive bladder cancer that has spread to nearby lymph nodes (but not distant organs). It may help shrink the cancer and improve treatment outcomes before or around planning major surgery.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
Hear when a new Urothelial Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.